Literature DB >> 16886141

Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants.

Jeffrey C Hageman1, Laura A Liedtke, Rebecca H Sunenshine, Larry J Strausbaugh, L Clifford McDonald, Fred C Tenover.   

Abstract

We conducted a survey in 2005 of infectious diseases consultants and asked about persistent bacteremia due to methicillin-resistant Staphylococcus aureus. Many consultants perceived an increase in the frequency of illness, and, when presented with vancomycin minimum inhibitory concentrations approaching the limit of the susceptible range, most consultants indicated that they would switch to newer antimicrobial agents for treatment.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16886141     DOI： 10.1086/506568

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  7 in total

1.  Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?

Authors:  Federico Pea; Pierluigi Viale
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

2.  Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aureus among methicillin-resistant isolates in Taiwan--SMART program, 2003.

Authors:  C-M Ho; P-R Hsueh; C-Y Liu; S-Y Lee; T-S Chiueh; J-M Shyr; S-M Tsao; Y-C Chuang; J-J Yan; L-S Wang; J-H Wang; M-W Ho; N Tien; J-J Lu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-02-13       Impact factor: 3.267

3.  Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus.

Authors:  David J Riedel; Elizabeth Weekes; Graeme N Forrest
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

4.  High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis.

Authors:  Jesse T Jacob; Carlos A DiazGranados
Journal:  Int J Infect Dis       Date:  2012-10-22       Impact factor: 3.623

5.  Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Majid Taati Moghadam; Alex van Belkum; Somayeh Yaslianifard; Davood Darban-Sarokhalil
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

Review 6.  Methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in Taiwan.

Authors:  Chien-Yu Lin; Jui-Hsing Wang; Kai-Hsiang Lin; Yu-Ling Ho; Cheng-Mao Ho
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2018 Jul-Sep

7.  Adjunctive rifampin for the treatment of Staphylococcus aureus bacteremia with deep infections: A meta-analysis.

Authors:  Huan Ma; Jie Cheng; Lengyue Peng; Yawen Gao; Guangli Zhang; Zhengxiu Luo
Journal:  PLoS One       Date:  2020-03-19       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.